In last trading session, Inozyme Pharma Inc (NASDAQ:INZY) saw 0.71 million shares changing hands with its beta currently measuring 1.29. Company’s recent per share price level of $1.25 trading at -$0.02 or -1.57% at ring of the bell on the day assigns it a market valuation of $80.31M. That closing price of INZY’s stock is at a discount of -524.0% from its 52-week high price of $7.80 and is indicating a premium of 0.8% from its 52-week low price of $1.24.
For Inozyme Pharma Inc (INZY), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.11. Splitting up the data highlights that, out of 6 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.37 in the current quarter.
Inozyme Pharma Inc (NASDAQ:INZY) trade information
Upright in the red during last session for losing -1.57%, in the last five days INZY remained trading in the red while hitting it’s week-highest on Friday, 02/14/25 when the stock touched $1.25 price level, adding 12.49% to its value on the day. Inozyme Pharma Inc’s shares saw a change of -54.87% in year-to-date performance and have moved -7.41% in past 5-day. Inozyme Pharma Inc (NASDAQ:INZY) showed a performance of -3.85% in past 30-days.
Wall Street analysts have assigned a consensus price target of 16 to the stock, which implies a rise of 92.19% to its current value. Analysts have been projecting 16 as a low price target for the stock while placing it at a high target of 16. It follows that stock’s current price would drop -1180.0% in reaching the projected high whereas dropping to the targeted low would mean a loss of -1180.0% for stock’s current value.
Inozyme Pharma Inc (INZY) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -35.73% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -16.59% while estimates for its earnings growth in next 5 years are of -5.45%.
Inozyme Pharma Inc (NASDAQ:INZY)’s Major holders
ADAGE CAPITAL PARTNERS GP, L.L.C. is the top institutional holder at INZY for having 5.73 million shares of worth $25.55 million. And as of 2024-06-30, it was holding 9.2484 of the company’s outstanding shares.
The second largest institutional holder is PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC, which was holding about 4.49 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.2563 of outstanding shares, having a total worth of $20.05 million.
On the other hand, Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund and Fidelity Select Portfolios – Biotechnology are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 4.13 shares of worth $5.17 million or 6.44% of the total outstanding shares. The later fund manager was in possession of 1.87 shares on Dec 31, 2024 , making its stake of worth around $2.33 million in the company or a holder of 2.91% of company’s stock.
